ISSN 1662-4009 (online)

ey0019.5-6 | Advances in clinical practice | ESPEYB19

5.6. Vitamin D level and fractures in children and adolescents: a systematic review and meta-analysis

C Zheng , H Li , S Rong , L Liu , K Zhen , K Li

Bone Miner Metab. 2021 Sep;39(5):851-857Abstract: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/34115219/In brief: Vitamin D plays a pivotal role in calcium homeostasis and bone health; a question is therefore frequently raised regarding the risk of fractures in children with vitamin D deficiency. This is more pertinent in safeguarding cases where it is not uncommon to fin...

ey0016.4-14 | Mechanism of the Year | ESPEYB16

4.14. IGF-2 preprograms maturing macrophages to acquire oxidative phosphorylation-dependent anti-inflammatory properties

L Du , L Lin , Q Li , K Liu , Y Huang , X Wang , K Cao , X Chen , W Cao , F Li , C Shao , Y Wang , Y Shi

To read the full abstract: Cell Metab. 2019 4;29:1363–1375.Mesenchymal stem and/or stromal cells (MSCs) regulate immune system and have been associated with inflammatory and autoimmune diseases. The IGF system is mainly known for its role in the regulation of growth, development and metabolism. A possible role of IGF-I in inflammation has recently been proposed [1, 2], whereas the e...

ey0020.3-1 | Novel Treatments for Rare Skeletal Disorders | ESPEYB20

3.1. Safety and efficacy of denosumab for fibrous dysplasia of bone

LF de Castro , Z Michel , K Pan , J Taylor , V Szymczuk , S Paravastu , B Saboury , GZ Papadakis , X Li , K Milligan , B Boyce , SM Paul , MT Collins , AM Boyce

In Brief: This phase 2 study investigated the effect of the RANKL inhibitor denosumab on fibrous dysplasia lesion activity, as well as the rebound in bone turnover after treatment discontinuation.Commentary: Denosumab is a humanized monoclonal antibody that inhibits RANKL with potent but transient antiosteoclastic effects, and discontinuation of denosumab treatment is associated with a rebound in bone turnover. In this study, eight women received high do...